Endogenous antibody response to SARS-CoV-2 in patients who received monoclonal antibodies against COVID-19: A systematic review

Andrea Lombardi; Cecilia Azzarà; Giulia Renisi; Giulia Viero; Andrea Gori; Alessandra Bandera

doi:10.1016/j.clicom.2022.08.003

Endogenous antibody response to SARS-CoV-2 in patients who received monoclonal antibodies against COVID-19: A systematic review

Clin Immunol Commun. 2022 Dec:2:106-109. doi: 10.1016/j.clicom.2022.08.003. Epub 2022 Aug 27.

Authors

Andrea Lombardi^{1

2}, Cecilia Azzarà¹, Giulia Renisi¹, Giulia Viero¹, Andrea Gori^{1

2}, Alessandra Bandera^{1

2}

Affiliations

¹ Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
² Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.

Abstract

Passive immunization with mAbs has been employed in COVID-19. We performed a systematic review of the literature assessing the endogenous humoral immune response against SARS-CoV-2 in patients treated with mAbs. Administration of mAbs in seronegative patients led to a reduction in both antibody titres and neutralizing activity against the virus.

Keywords: Endogenous immune response; Monoclonal antibodies; Neutralization; SARS-CoV-2; Spike protein.